Certara Inc
NASDAQ:CERT

Watchlist Manager
Certara Inc Logo
Certara Inc
NASDAQ:CERT
Watchlist
Price: 10.74 USD 0.28% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Certara Inc?
Write Note

Certara Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Certara Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Certara Inc
NASDAQ:CERT
Additional Paid In Capital
$1.2B
CAGR 3-Years
10%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Additional Paid In Capital
$2.2B
CAGR 3-Years
25%
CAGR 5-Years
26%
CAGR 10-Years
22%
Inspire Medical Systems Inc
NYSE:INSP
Additional Paid In Capital
$1B
CAGR 3-Years
27%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Additional Paid In Capital
$823.9m
CAGR 3-Years
200%
CAGR 5-Years
138%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Additional Paid In Capital
$1.2B
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Additional Paid In Capital
$2.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Certara Inc
Glance View

Market Cap
1.7B USD
Industry
Health Care

Certara Inc., founded in 2008, has emerged as a pivotal player in the realm of virtual drug development, leveraging its sophisticated model-based drug development technology to transform how pharmaceutical companies strategize and optimize drug discovery. The company's core strength lies in its comprehensive suite of biosimulation software and services, which predict how drugs behave in the human body. This revolutionary approach allows pharmaceutical companies to refine their drug development processes, increase efficiency, and reduce the time and cost associated with bringing new drugs to market. By providing insights into drug interactions, efficacy, and safety, Certara aids its clients in making informed decisions early in the development cycle, essentially becoming an indispensable ally in navigating the complex and costly landscape of drug development. Certara generates revenue primarily through software licensing and consulting services, establishing long-term partnerships with its diverse clientele, which includes over 1,850 companies worldwide, including prominent pharmaceutical giants and regulatory agencies. By embedding itself into the critical processes of drug development, Certara garners not just the upfront licensing fees but also ongoing consulting fees that allow pharmaceutical companies to fine-tune and optimize their drug development strategies continuously. As healthcare industries place increasing emphasis on precision medicine and personalized healthcare, Certara's role as a guide in these innovations becomes even more pronounced, ensuring its financial health and relevance in a highly competitive field. The company's growth reflects a keen understanding of its niche, capitalizing on its unique offerings to remain at the forefront of scientific innovation.

CERT Intrinsic Value
11.44 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Certara Inc's Additional Paid In Capital?
Additional Paid In Capital
1.2B USD

Based on the financial report for Dec 31, 2023, Certara Inc's Additional Paid In Capital amounts to 1.2B USD.

What is Certara Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
18%

Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Certara Inc have been 10% over the past three years , 18% over the past five years .

Back to Top